The article title identifies an original research study published in Frontiers in Immunology that examined the immunogenicity of sequential conjugate and non-conjugate pneumococcal vaccination in patients receiving dialysis and in kidney transplant recipients. The title indicates the investigation included a 12-month serological follow-up to assess vaccine-induced antibody responses over time.
The supplied source material for this rewrite contains only journal header and navigation content from Frontiers in Immunology; the full manuscript text, figures, tables, and numeric data were not included. As a result, the narrative below is limited to what is explicitly reported in the available source and to transparent statements about missing details.
According to the article title, the central objective was to evaluate the immunogenicity of a sequential vaccine strategy using a conjugate pneumococcal vaccine followed by a non-conjugate pneumococcal vaccine. The populations identified are dialysis patients and kidney transplant recipients, with serological outcomes monitored over a 12-month period.
The provided extract does not include an explicit statement of primary or secondary endpoints, hypotheses, or predefined immunological thresholds. Therefore, specific objective wording, primary endpoints, and hypotheses were not reported in the available source.
The title specifies two clinical groups: patients on dialysis and kidney transplant recipients. No further demographic, geographic, or clinical inclusion/exclusion criteria, nor sample sizes, were present in the supplied excerpt. Details such as age distribution, comorbidities, immunosuppressive regimens for transplant recipients, dialysis modality, or recruitment sites were not reported in the provided material.
The study title states a sequential regimen involving a conjugate pneumococcal vaccine followed by a non-conjugate pneumococcal vaccine. The title does not name the specific vaccine formulations, manufacturers, doses, timing between doses, route of administration, or whether a single sequence or multiple schedules were compared. Those operational details were not included in the source excerpt provided for this task.
The title indicates a 12-month serological follow-up, implying serial measurement of antibody responses over a one-year period after vaccination. The supplied source does not include which serological assays were used (for example, serotype-specific IgG ELISA, opsonophagocytic activity), the serotypes measured, timing of blood draws, definitions of seroprotection or seroconversion, or whether cellular immunity was assessed. Those assay and endpoint details were not reported in the available source.
The provided material does not contain any results, numerical outcomes, or summary statements about immunogenicity, durability of responses at 12 months, differences between dialysis patients and transplant recipients, or comparisons between vaccine formulations. No data on antibody titers, response rates, statistical significance, or safety and reactogenicity were included. Therefore, no results can be summarized from the supplied source.
Because the article text and discussion were not part of the supplied content, the manuscript’s interpretation of findings, clinical implications for vaccination policy in immunocompromised kidney patients, and recommendations for practice or future research cannot be paraphrased or inferred from this source.
The supplied extract does not present the authors’ conclusions. Any statement about the effectiveness, recommended use, or comparative performance of sequential conjugate and non-conjugate pneumococcal vaccination in dialysis or transplant patients would be speculative and is therefore not provided here.
This editorial rewrite is constrained by the content provided: only bibliographic/journal header material and the article title were included. The absence of the manuscript body means methods, results, statistical analyses, adverse event reporting, author affiliations, funding sources, and conflicts of interest were not available to extract or summarize. Where specific study details are required for clinical decision-making or literature synthesis, the original published article must be consulted.
The title and journal (Frontiers in Immunology) are provided in the source metadata. To obtain full methods, results, figures, and the authors’ interpretations, readers should retrieve the complete article on the Frontiers in Immunology website or via the article DOI/link referenced in the original citation. The full text will contain the necessary details omitted from the supplied header excerpt.
Note: This rewritten summary preserves only the facts present in the supplied source content and explicitly states where study details were not reported in the provided material.